Laurent Humeau

Laurent Humeau, listed as senior executive, appears in our data through filings on Inovio Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 9 March 2019 to 26 February 2026, the count stands at 53 filings.

In open-market terms, that means 2 purchases worth €54k on one side and 5 sales worth €888k on the other. Netting one side against the other leaves €834k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 23 share grants and 23 option exercises.

The newest entry dates from 27 February 2026: an option exercise, in Inovio Pharmaceuticals, Inc. The most recent open-market purchase was published on 4 September 2019, 2,622 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.